{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:50:40Z","timestamp":1792788640175,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF22OC0074083"],"award-info":[{"award-number":["NNF22OC0074083"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Extended dual pathway inhibition (DPI) with aspirin and rivaroxaban is recommended in high-risk patients with chronic coronary syndrome (CCS). In the 2024 update of the European Society of Cardiology guidelines on CCS, the high-risk criteria were revised. In the COMPASS cohort, we evaluated net clinical benefit of DPI according to baseline risk as defined by the ESC criteria in CCS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>CCS patients randomized to aspirin alone or DPI (n = 15 429) were risk stratified using the 2024 ESC criteria. Endpoints included major adverse cardiovascular events (MACE), all-cause death, fatal\/critical organ bleeding, and composite adverse events (MACE and bleeding). Net clinical benefit was the 30-month absolute risk difference combining MACE and bleeding. High-risk status was associated with higher 30-month incidences of MACE (6.4% vs. 5.0%, HR 1.33, 95% CI 1.09\u20131.63) and composite adverse events [7.1% vs. 5.7%, HR 1.31 (1.09\u20131.58)] but not all-cause death or bleeding. DPI reduced MACE [low risk: HR 0.66 (0.45\u20130.95); high risk: HR 0.77 (0.66.\u22120.91); P-value for interaction 0.42] and all-cause death [low risk: 0.78 (0.53\u20131.14); high risk: HR 0.78 (0.64\u20130.94), P-value for interaction 0.99]. DPI provided similar net clinical benefit in low-risk [30-month risk difference \u22121.77% (\u22123.88\u20130.33), HR 0.79 (0.56\u20131.11)] and high-risk patients [30-month risk difference \u22122.06% (\u22123.20\u22120.91), HR 0.80 (0.69\u20130.93); P-value for interaction 0.94].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In CCS patients, DPI reduced all-cause death and MACE while increasing major bleeding. The 2024 ESC criteria performed poorly in terms of distinguishing patients at high vs. low ischaemic risk, making them inadequate to provide guidance for DPI use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag008","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:49:09Z","timestamp":1769690949000},"page":"167-175","source":"Crossref","is-referenced-by-count":1,"title":["Net clinical benefit of extended dual pathway inhibition in chronic coronary syndrome as classified by the 2024 ESC criteria: a COMPASS substudy"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7150-7704","authenticated-orcid":false,"given":"Morten","family":"W\u00fcrtz","sequence":"first","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Palle Juul-Jensens Boulevard 99, Aarhus 8200 ,","place":["Denmark"]},{"name":"Department of Cardiology, G\u00f8dstrup Hospital , Hospitalsparken 15, Herning 7400 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-3615","authenticated-orcid":false,"given":"Kevin Kris Warnakula","family":"Olesen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Palle Juul-Jensens Boulevard 99, Aarhus 8200 ,","place":["Denmark"]},{"name":"Department of Cardiology, G\u00f8dstrup Hospital , Hospitalsparken 15, Herning 7400 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilong","family":"Yi","sequence":"additional","affiliation":[{"name":"School of Public Health, Ottawa University , K1Y 4W7 Ottawa ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4126-1285","authenticated-orcid":false,"given":"John W","family":"Eikelboom","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, Hamilton Health Sciences and McMaster University , L8L 2X2 Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4310-6433","authenticated-orcid":false,"given":"Michael","family":"Maeng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Palle Juul-Jensens Boulevard 99, Aarhus 8200 ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Aarhus 8000 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026051910565649200_pvag008-B1","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026051910565649200_pvag008-B2","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/eurheartj\/ehv443","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","volume":"37","author":"Udell","year":"2016","journal-title":"Eur Heart J"},{"key":"2026051910565649200_pvag008-B3","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026051910565649200_pvag008-B4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","article-title":"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial","volume":"394","author":"Bhatt","year":"2019","journal-title":"Lancet"},{"key":"2026051910565649200_pvag008-B5","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"2026051910565649200_pvag008-B6","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/eurheartj\/ehab785","article-title":"Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score","volume":"43","author":"Wurtz","year":"2022","journal-title":"Eur Heart J"},{"key":"2026051910565649200_pvag008-B7","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1016\/j.jacc.2019.02.079","article-title":"Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial","volume":"73","author":"Anand","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026051910565649200_pvag008-B8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.120.046048","article-title":"The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease","volume":"142","author":"Steffel","year":"2020","journal-title":"Circulation"},{"key":"2026051910565649200_pvag008-B9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.amjcard.2020.06.031","article-title":"A novel model for prediction of thromboembolic and cardiovascular events in patients without atrial fibrillation","volume":"131","author":"Steensig","year":"2020","journal-title":"Am J Cardiol"},{"key":"2026051910565649200_pvag008-B10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/ehjcvp\/pvae017","article-title":"Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy","volume":"10","author":"Wurtz","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051910565649200_pvag008-B11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2026051910565649200_pvag008-B12","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/nejmoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2026051910565649200_pvag008-B13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.cjca.2017.06.001","article-title":"Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial","volume":"33","author":"Bosch","year":"2017","journal-title":"Can J Cardiol"},{"key":"2026051910565649200_pvag008-B14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamacardio.2020.4390","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026051910565649200_pvag008-B15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"2026051910565649200_pvag008-B16","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"2026051910565649200_pvag008-B17","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"2026051910565649200_pvag008-B18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.114.013570","article-title":"Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberte paclitaxel-eluting coronary stent placement","volume":"131","author":"Garratt","year":"2015","journal-title":"Circulation"},{"key":"2026051910565649200_pvag008-B19","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","article-title":"Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54","volume":"37","author":"Bonaca","year":"2016","journal-title":"Eur Heart J"},{"key":"2026051910565649200_pvag008-B20","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"2026051910565649200_pvag008-B21","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026051910565649200_pvag008-B22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jacc.2017.11.050","article-title":"Ticagrelor for secondary prevention of atherothrombotic events in patients with multivessel coronary disease","volume":"71","author":"Bansilal","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026051910565649200_pvag008-B23","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026051910565649200_pvag008-B24","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026051910565649200_pvag008-B25","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/eurheartj\/ehw454","article-title":"Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis","volume":"38","author":"Halvorsen","year":"2017","journal-title":"Eur Heart J"},{"key":"2026051910565649200_pvag008-B26","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"Sorensen","year":"2009","journal-title":"Lancet"},{"key":"2026051910565649200_pvag008-B27","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1016\/j.jacc.2019.04.046","article-title":"Association of multiple enrichment criteria with ischemic and bleeding risks among COMPASS-eligible patients","volume":"73","author":"Darmon","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag008\/66639687\/pvag008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/3\/167\/66639687\/pvag008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/3\/167\/66639687\/pvag008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:57:06Z","timestamp":1779202626000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/3\/167\/8445293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,1,30]]},"published-print":{"date-parts":[[2026,5,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag008","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,1,30]]}}}